WebDec 5, 2024 · December 5, 2024 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA) … WebDec 12, 2024 · The data demonstrated a consistent safety profile for cilta-cel and no new safety signals were observed with longer follow-up. 1 In 18-month follow-up data presented at ASCO 2024, the most common ...
Minhee Kim posted on LinkedIn
WebWe’re excited to share that our analytics platform, called OPS, devised with Lynxx, was awarded 'runner up' in the Excellence in Moving People category at the 2024 CILTA Awards for Excellence. WebNov 5, 2024 · Introduction: There are several treatment options for patients (pts) with progressive multiple myeloma (MM) who are refractory to lenalidomide but most pts relapse shortly after receiving salvage treatment. Cilta-cel is a CAR-T therapy expressing 2 BCMA-targeting, single-domain antibodies that demonstrated early, deep, and durable … how to stop a dog moulting
FDA Approves Second CAR-T Therapy for Multiple Myeloma
WebJun 1, 2024 · The data demonstrated a consistent safety profile for cilta-cel and no new safety signals were observed with longer follow-up. 1 The most common hematologic adverse events (AEs) observed in the ... WebNov 2, 2024 · CILTA’s award winners included: Young Professional of the Year: Dr Catherine Lou from Victoria University. "Catherine has been a key proponent for entrepreneurship in the logistics and supply chain data … WebMay 26, 2024 · CARTITUDE-1 (NCT03548207) is a Phase 1b/2, open-label, multicenter study evaluating the safety and efficacy of cilta-cel in adults with relapsed and/or … how to stop a dog licking you